Bloomberg Anywhere Remote Login Bloomberg Terminal Demo Request


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last $0.0001 USD
Change Today 0.00 / 0.00%
Volume 0.0
IXSBF On Other Exchanges
As of 8:10 PM 09/24/15 All times are local (Market data is delayed by at least 15 minutes).

innexus biotechnology inc (IXSBF) Snapshot

Previous Close
Day High
Day Low
52 Week High
12/31/14 - $0.0015
52 Week Low
12/26/14 - $0.0001
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield

Related News

No related news articles were found.

innexus biotechnology inc (IXSBF) Related Businessweek News

No Related Businessweek News Found

innexus biotechnology inc (IXSBF) Details

InNexus Biotechnology, Inc., a development stage company, engages in the commercialization of monoclonal antibodies based on its Dynamic Cross Linking (DXL) technology. Its DXL technology seeks to improve the therapeutic potency of existing monoclonal antibody products by increasing the binding to target antigen, enhancing antibody effector functions, and installing new properties into antibodies. The company’s products in pipeline include DXL625, a monoclonal antibody in late stage pre-clinical development produced with enhanced binding kinetics and effector functions for the treatment of B cell non-Hodgkins lymphoma (NHL) and DXLr120, a recombinant DXL anti-CD20 antibody being developed for the treatment of B cell NHL cancer; DXL702, a monoclonal antibody being developed for the treatment of metastatic breast cancer; and DXL1218, which targets an antigen designated epidermal growth factor receptor that is over expressed in metastatic colorectal cancer and in squamous cell carcinomas of the head and neck. It has collaboration agreements with XERIS Pharmaceuticals, Genhelix, Evogenix, Affimed, and Corixa. InNexus Biotechnology, Inc. is headquartered in Vancouver, Canada.

innexus biotechnology inc (IXSBF) Top Compensated Officers

No compensation data is available at this time for the top officers at this company.

Executives, Board Directors


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
IXSBF:US $0.00 USD 0.00

IXSBF Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for IXSBF.
View Industry Companies

Industry Analysis


Industry Average

Valuation IXSBF Industry Range
Price/Earnings -- Not Meaningful
Price/Sales -- Not Meaningful
Price/Book -- Not Meaningful
Price/Cash Flow -- Not Meaningful
TEV/Sales -- Not Meaningful

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact INNEXUS BIOTECHNOLOGY INC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at